{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:05:17Z","timestamp":1792458317063,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ard.2026.05.029","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:26:22Z","timestamp":1786073182000},"page":"1729-1742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carle","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihi","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Pink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique R.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Leszczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose U.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chahin","family":"Pachai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Rabbat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Sardinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Vritzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vaile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ard.2026.05.029_bib0001","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.ard.2026.05.029_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101694","article-title":"Pathogenesis of psoriatic arthritis","volume":"35","author":"Stober","year":"2021","journal-title":"Best Pract Res Clin Rheumatol."},{"issue":"1","key":"10.1016\/j.ard.2026.05.029_bib0003","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: state of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin Med (Lond)."},{"issue":"2","key":"10.1016\/j.ard.2026.05.029_bib0004","doi-asserted-by":"crossref","first-page":"159","DOI":"10.46497\/ArchRheumatol.2024.10710","article-title":"Unmet needs in psoriatic arthritis, a narrative review","volume":"39","author":"Lopez-Medina","year":"2024","journal-title":"Arch Rheumatol."},{"issue":"2","key":"10.1016\/j.ard.2026.05.029_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003912","article-title":"Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b\/4 randomised safety study","volume":"10","author":"Buch","year":"2024","journal-title":"RMD Open."},{"issue":"1","key":"10.1016\/j.ard.2026.05.029_bib0006","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"10.1016\/j.ard.2026.05.029_bib0007","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"10.1016\/j.ard.2026.05.029_bib0008","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.ard.2026.05.029_bib0009","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.05.029_bib0010","series-title":"SOTYKTU (deucravacitinib) package insert [Internet]","year":"2026"},{"key":"10.1016\/j.ard.2026.05.029_bib0011","series-title":"SOTYKTU (deucravacitinib) summary of product characteristics [Internet]","year":"2026"},{"issue":"2","key":"10.1016\/j.ard.2026.05.029_bib0012","doi-asserted-by":"crossref","first-page":"s532","DOI":"10.25251\/skin.10.supp.532","article-title":"Deucravacitinib in moderate to severe plaque psoriasis: 5-year, long-term safety and efficacy results from the phase 3 POETYK PSO-1, PSO-2, and LTE trials","volume":"9","author":"Armstrong","year":"2025","journal-title":"J of Skin."},{"issue":"502","key":"10.1016\/j.ard.2026.05.029_bib0013","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med."},{"issue":"20","key":"10.1016\/j.ard.2026.05.029_bib0014","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J Med Chem."},{"issue":"3","key":"10.1016\/j.ard.2026.05.029_bib0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/pst.291","article-title":"Gatekeeping procedures with clinical trial applications","volume":"6","author":"Dmitrienko","year":"2007","journal-title":"Pharm Stat"},{"issue":"suppl 9","key":"10.1016\/j.ard.2026.05.029_bib0016","first-page":"LB20","article-title":"Efficacy and safety of deucravacitinib up to week 52: a multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drugs [abstract]","volume":"77","author":"van der Heijde","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ard.2026.05.029_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/art.70280","article-title":"Deucravacitinib in active psoriatic arthritis: efficacy and safety up to 52 weeks from the randomized, double-blind, phase 3 POETYK PsA-2 trial","author":"Mease","year":"2026","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.ard.2026.05.029_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2024.105807","article-title":"Clinical enthesitis in patient with psoriatic arthritis, a systematic literature review with metaanalysis","volume":"92","author":"Pignon","year":"2025","journal-title":"Joint Bone Spine."},{"issue":"9999","key":"10.1016\/j.ard.2026.05.029_bib0019","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.ard.2026.05.029_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005785","article-title":"Using ultrasound to define inflammatory and non-inflammatory phenotypes in difficult-to-treat psoriatic arthritis","volume":"11","author":"Zabotti","year":"2025","journal-title":"RMD Open."},{"issue":"8","key":"10.1016\/j.ard.2026.05.029_bib0021","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s13555-024-01224-x","article-title":"Deucravacitinib improves patient-reported outcomes in patients with moderate to severe psoriasis: results from the phase 3 randomized POETYK PSO-1 and PSO-2 trials","volume":"14","author":"Armstrong","year":"2024","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"1","key":"10.1016\/j.ard.2026.05.029_bib0022","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol."},{"issue":"7","key":"10.1016\/j.ard.2026.05.029_bib0023","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/jdv.20553","article-title":"Deucravacitinib in plaque psoriasis: four-year safety and efficacy results from the phase 3 POETYK PSO-1, PSO-2 and long-term extension trials","volume":"39","author":"Armstrong","year":"2025","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"1","key":"10.1016\/j.ard.2026.05.029_bib0024","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol."},{"issue":"10","key":"10.1016\/j.ard.2026.05.029_bib0025","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ard.2025.05.023","article-title":"Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study","volume":"84","author":"Kivitz","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"10.1016\/j.ard.2026.05.029_bib0026","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.1016\/S2665-9913(23)00264-3","article-title":"Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis","volume":"5","author":"Eder","year":"2023","journal-title":"Lancet Rheumatol."},{"issue":"12","key":"10.1016\/j.ard.2026.05.029_bib0027","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.ard.2025.08.006","article-title":"Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study","volume":"84","author":"Mease","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"10.1016\/j.ard.2026.05.029_bib0028","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"10.1016\/j.ard.2026.05.029_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002939","article-title":"Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study","volume":"9","author":"Coates","year":"2023","journal-title":"RMD Open."},{"issue":"2","key":"10.1016\/j.ard.2026.05.029_bib0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3899\/jrheum.210346","article-title":"Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with rheumatoid arthritis: results from RA-BEYOND","volume":"49","author":"van der Heijde","year":"2022","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.05.029_bib0031","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.reuma.2023.06.007","article-title":"Real-world apremilast use in biologic-na\u00efve psoriatic arthritis patients. Data from Spanish clinical practice","volume":"20","author":"Gratac\u00f3s-Masmitja","year":"2024","journal-title":"Reumatol Clin (Engl Ed)."},{"issue":"suppl 1","key":"10.1016\/j.ard.2026.05.029_bib0032","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ard.2025.05.117","article-title":"OP0095 Efficacy and safety of deucravacitinib up to week 52 from POETYK PsA-2: a multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with psoriatic arthritis","volume":"84","author":"Mease","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"10.1016\/j.ard.2026.05.029_bib0033","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"13","key":"10.1016\/j.ard.2026.05.029_bib0034","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1016\/j.ard.2026.05.029_bib0035","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis."},{"issue":"16","key":"10.1016\/j.ard.2026.05.029_bib0036","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med."},{"issue":"16","key":"10.1016\/j.ard.2026.05.029_bib0037","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726003407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726003407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:20:15Z","timestamp":1789154415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726003407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0003496726003407"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.05.029","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}